Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
46.58
-0.31 (-0.66%)
At close: Nov 20, 2024, 4:00 PM
45.00
-1.58 (-3.39%)
Pre-market: Nov 21, 2024, 5:25 AM EST
Tarsus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for TARS stock have an average target of 54.2, with a low estimate of 41 and a high estimate of 65. The average target predicts an increase of 16.36% from the current stock price of 46.58.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TARS stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $36 → $41 | Hold | Maintains | $36 → $41 | -11.98% | Nov 15, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $63 → $65 | Buy | Maintains | $63 → $65 | +39.54% | Nov 14, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $61 → $63 | Buy | Reiterates | $61 → $63 | +35.25% | Aug 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $57 → $61 | Strong Buy | Maintains | $57 → $61 | +30.96% | May 13, 2024 |
| Barclays | Barclays | Buy Maintains $50 → $60 | Buy | Maintains | $50 → $60 | +28.81% | May 10, 2024 |
Financial Forecast
Revenue This Year
166.20M
from 17.45M
Increased by 852.60%
Revenue Next Year
289.53M
from 166.20M
Increased by 74.21%
EPS This Year
-3.87
from -4.62
EPS Next Year
-2.20
from -3.87
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 174.8M | 342.0M | 621.5M | ||
| Avg | 166.2M | 289.5M | 496.2M | ||
| Low | 154.7M | 224.4M | 382.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 901.8% | 105.8% | 114.6% | ||
| Avg | 852.6% | 74.2% | 71.4% | ||
| Low | 786.6% | 35.0% | 32.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -3.65 | -0.85 | 3.53 |
| Avg | -3.87 | -2.20 | 1.54 |
| Low | -4.13 | -3.82 | -1.92 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.